Australia's most trusted
source of pharma news
Wednesday, 29 July 2026
Posted 29 July 2026 AM
After an enterprise-wide review of its cost base, GSK has announced a three-year restructure that will result in AU$3.6 billion in savings annually with the company's new Australian CEO Luke Miels declining to say - for now - how many jobs will go.
"I want my team to have the chance to discuss this with our people first," he said.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.